THE PRINCIPLE OF
HIGH PRODUCTION CAPACITY
In recent years, Blanver has become one of the largest suppliers of APIs for the manufacture of antiretroviral drugs and for the treatment of diseases of the Central Nervous System. We adhere to the control standards of the European Union, which are recognized by ANVISA as equivalent.
COMMITMENT TO HIGHEST QUALITY
Blanver holds the Good Manufacturing Practices certificate issued by ANVISA, which is now part of the Pharmaceutical Inspection Cooperation Scheme (PIC/S).
Another legal obligation, excellence, is a commitment that Blanver keeps to its customers and employees.
Therefore, the Quality Policy guides all areas of the company’s activity and establishes essential practices so that the quality and high efficiency of all products are always safely delivered.
The need for less dependence on the international market of active pharmaceutical ingredients and the search for qualified domestic raw materials in the pharmaceutical market encourages drug manufacturers to seek affiliated pharmaceutical companies to ensure patient access to innovative quality treatments.
Quality and safety
The production of active pharmaceutical ingredients (APIs) of the highest quality for the pharmaceutical industry in Brazil and around the world follows rigorous processes that are fundamental to a better quality of life.
During all production and administrative phases, documentation is managed in such a way that all operations are traceable, ensuring better control of tax, legal, and production requirements.
Blanver has expanded its national area of activity through strategic import cooperations at the international level with a view to future exports. These alliances also help increase production capacity, develop new APIs, and open the door to new contracts and partners.
Mission and values
The investment in Active Pharmaceutical Ingredients reflects the company's mission and values of expanding access to innovative, high-quality treatments for patients.
INVESTMENTS THAT DELIVER RESULTS
infrastructure and technology
The company's infrastructure enables it to conduct research and produce inputs on a large scale while maintaining the strictest quality and safety standards.
Blanver has a multidisciplinary team that works in an integrated way to meet internal needs and those of our customers.
Commitment to excellence
None of Blanver's achievements would be possible without the commitment and dedication of the company's people who work actively every day to deliver excellent products and the best results.
STRATEGIC INNOVATION THAT CREATES VALUE
Blanver develops and implements innovative chemical processes to offer to the market Active Pharmaceutical Ingredients used in the manufacture of generic and reference drugs. The company has the technical knowledge of multidisciplinary teams, including the participation of chemists and pharmacists, among them masters and physicians, who actively participate in the development of efficient and effective processes and oversee all operations in accordance with good manufacturing practices and appropriate procedures.
• API analytical methods are validated in accordance with RDC 166/2017 (ANVISA) and the ICH Q2 Guide.
• The stability studies that determine the validity period of APIs comply with RDC 318/2019 (ANVISA) and other standards from ANVISA, the FDA, and other regulatory agencies.
Rua Doutor Mario Augusto Pereira, 100, Galpão B, Jardim São Paulo, Taboão da Serra, São Paulo, CEP: 06767-330 • © Blanver 2020, Todos os direitos reservados